Abstract: Stable lung surfactant compositions are provided, as well as methods for their preparation, modification, formulation, assay, and therapeutic use.

Abstract: Polypeptide analogs of human the human lung surfactant protein, SP-C, are provided. The polypeptides have the following structure: ##STR1## wherein A is H or Phe, B is Phe or Trp, and C is Ile, Leu, or Ser. They exhibit surfactant activity and are useful in the treatment of respiratory distress syndromes in premature infants and adults.

Abstract: A solid form of oral administration of isosorbide 5-mononitrate with a controlled, pH-independent release of the active substance in the gastro-intestinal tract is constituted by a pellet coated with a depot layer and a release prolonging lacquer layer. The lacquer layer contains ethyl cellulose and polymethacrylate in a weight ratio from 3:1 to 3:2. The new form of administration is characterized in that it is less costly to produce.

Abstract: A compound of the formula I ##STR1## Wherein all the variables are defined in the specification. The compounds are used for controlling Helicobacter bacteria.

Abstract: Recombinant materials for the production of low molecular weight hydrophobic lung surfactant proteins are disclosed and claimed. The monomeric forms of the proteins from human and canine sources have apparent molecular weights of about 5 kd and form dimers under some conditions. The availability of these recombinant materials permits production of large amounts of these proteins through recombinant techniques and permits the use of these proteins in pharmaceutical compositions in the treatment of respiratory deficiency syndromes.

Abstract: 8-phenalkoxyimidazo?1,2-a!pyridinium salts are useful for controlling Helicobacter bacteria. Medicament compositions based on such compounds are prepared and used for the noted purpose.

Abstract: Described are compounds of formula (I) in which R1,R2,R3,R4,R5,R6,R7, m,n,p, and q are as defined in the description. Such compounds are suitable for use against Helicobacter bacteria.

Abstract: Epimers of the compound having the formula (I) are disclosed, both in their pure form and mixed in any desire mix ratio.

Abstract: The invention describes a process for the epimer enrichment of compounds of formula (I) by silation, fractionated crystallization and acid hydrolysis.

Abstract: This invention relates to novel compounds of formula (I) and their therapeutic use in the treatment of gastrointestinal diseases.

Abstract: Compounds of formula (I), in which one of the substituents R1 or R2 stands for hydrogen, 1-6C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, benzyloxy or totally or partially fluorine-substituted 1-4C-alkoxy, and the other stands for totally or partially fluorine-substituted 1-4C-alkoxy, and R3 stands for phenyl, pyridyl, R31, R32 and R33-substituted phenyl or R34, R35, R36 and R37-substituted pyridyl, in which R31 stands for hydroxy, halogen, cyano, carboxyl, trifluoromethyl 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl, 1-4C-alkylcarbonyl, 1-4C-alkylcarbonyloxy, amino, mono- or di-1-4C-alkylamino or 1-4C-alkylcarbonylamino; R32 stands for hydrogen, hydroxy, halogen, amino, trifluoromethyl, 1-4C-alkyl or 1-4C-alkoxy; R33 stands for hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy; R34 stands for hydroxy, halogen, cyano, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonyl or amino; R35 stands for hydrogen, halogen, amino or 1-4C-alkyl; R36 stands for hydrogen or halogen; and R37 stands for hydrogen or haloge

Abstract: Compounds of formula I ##STR1## wherein R1, R2, R3, R4, R5, R6, X, n and A have the meanings as given in the description, can be used for combatting Helicobacter bacteria.

Abstract: The invention relates to novel compounds of the formula I ##STR1## and the therapeutic use thereof.

Abstract: An aqueous preparation for receiving and stabilising micro gas bubbles for use as echo contrast media containing polyoxyethylene/polyoxypropylene polymers and negatively charged phospholipids, which is suitable for demonstration of the left ventricle, is indicated.

Abstract: Substituted heteroarylalkylthiopyridines of the formula (I) ##STR1## are suitable for treating conditions caused by Helicobacter bacteria, in particular the strain Helicobacter pylori.

Abstract: Compounds of formula (I) ##STR1## wherein R1 stands for alkyl or R5-substituted alkylene; R2 stands for alkyl; R3 stands for hydrogen, halogen, --CHO (formyl), hydroxymethyl, nitro, amino, or the substituent --CH.sub.2 O--COR7; R4 stands for halogen or the substituent --A--B--R6; R5 stands for furyl, thienyl, tetrahydrofuryl, phenyl or phenyl substituted by one or two identical or different substituents from the group composed of halogen, alkyl, alkoxy, nitro, --NH--CO--NH.sub.2 (ureido), amino, alkylcarbonyl-amino and alkoxycarbonylamino; R7 stands for alkyl, alkoxy-alkyl, alkoxycarbonyl-alkyl or carboxy-alkyl; A stands for O (oxygen) or NH; B stands for a bond, --CH.sub.2 -- (methylene) or --CH.sub.2 CH.sub.2 -- (1,2-ethylene); and n stands for the number 0 or 1; are useful for preventing and treating gastrointestinal disorders.

Abstract: Optically pure diaryl compounds of formula (I), in which the substituents and symbols have the meanings indicated in the description are proposed as active ingredients in medicinal preparations for treating tumorous diseases.

Abstract: The invention relates to a process for the preparation of optically pure 1,4-dihydropyridinemonocarboxylic acids of the formula I ##STR1## in which the substituents have the meanings mentioned in the description.

Abstract: The invention relates to the use of 1,4-dihydropyridines of the formula (I), in which the substituents and symbols are as defined in the description, for the preparation of medicaments for the treatment of dermatoses.

Abstract: Compounds of formula (I) ##STR1## in which R1, R2 and X have the meanings given in the specification, and their salts and N oxides are new agents for the treatment of bronchial conditions and dermatitis.